title: [What is new in antithrombotic treatment?].
abstract: Real progresses have been made during the past years in the comprehension of hemostasis mechanisms, along with rising of new antithrombotic drugs. The later include: 1) direct inhibitors of thrombin such as hirudin, bivalirudin, argatroban, melagatran and ximelagatran; 2) inhibitors of factor Xa such as the synthetic pentasaccharid and DX-9065a; 3) inhibitors of factor IXa; 4) inhibitors of tissue factor-factor VIIa complex such as tissue factor pathway inhibitor (TFPI) or NAPc2 (nematode anticoagulant peptide); 5) drugs enhancing endogenous anticoagulant activity, such as protein C or activated protein C; 6) drugs modulating endogenous fibrinolytic activity. These new drugs are promising a real decrease in mortality and morbidity due to venous thrombo-embolic disease, which is considered as a public health issue. Both physicians and biologists are concerned by these new antithrombotic agents, the former to think about new treatment strategies, the later to monitore, if necessary, the effects of such new drugs. Our review does not include antiplatelet agents which are indicated only in arterial thrombosis.
authors.affiliation: Services médicaux, Hôpital militaire d'instruction Mohammed-V, Rabat, Maroc.
authors.forename: M
authors.initials: M
authors.lastname: Mikdame
authors.forename: A
authors.initials: A
authors.lastname: Kharchafi
authors.forename: F
authors.initials: F
authors.lastname: Toloune
authors.forename: M I
authors.initials: MI
authors.lastname: Archane
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological; D013923:Thromboembolism / Q000188:drug therapy
chemical_list: D005343:Fibrinolytic Agents
vernacular_title: Quoi de neuf dans le traitement antithrombotique?